Diagnostic value of pyruvate kinase isoenzyme type M2 in colon cancer proven with colonoscopy

Document Type : Original Article


1 Department of Internal Medicine, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Laboratory Medicine, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Colonoscopy is the gold standard for colon cancer screening; it is also associated with a high cost and complication. Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed M2 pyruvate kinase (M2-PK). The aim of this study was to determine the diagnostic accuracy of fecal M2-PK for colon cancer. Materials and Methods: Forty-nine patients with colon cancers and 49 healthy controls were selected consecutively among individuals undergoing screening colonoscopy for various indications. The diagnosis was confirmed by histology. M2-PK measurements were done by enzyme-linked immunosorbent assay of fecal occult blood test (FOBT) and immunological FOBT (IFOBT) according to the manufacturer's instructions. Results: M2-PK > 9 (U/mL) was the best cutoff point in the detection of colon cancers. In this cutoff point, sensitivity and specificity were 87.8% and 91.8%, respectively, and accuracy was 89.8%. The sensitivity and specificity of IFOBT were 93.9% and 100%, respectively, and accuracy was 96.9%. The sensitivity and specificity of FOBT were 65.3% and 100%, respectively, and accuracy was 82.6%. Conclusion: IFOBT with high sensitivity and specificity and accuracy and low cost is the best fecal screening test. The current study suggests that fecal M2-PK can be used for high-risk colon cancer patients and negative IFOBT that refused colonoscopy as a precolonoscopy screening test.


Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.  Back to cited text no. 1
Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968;65:281-393.  Back to cited text no. 2
Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 2006;12:7007-11.  Back to cited text no. 3
Bresalier RS. Colorectal cancer. In: Feldman M, Friedman LS, Brandt LJ, eds. Schleisenger's and Fordtran's Gastrointestinal and Liver Disease. 9th ed.. Philadelphia: Saunders; 2010. p. 2191-238.  Back to cited text no. 4
Warburg O. On the origin of cancer cells. Science 1956;123:309-14.  Back to cited text no. 5
Iqbal MA, Gupta V, Gopinath P, Mazurek S, Bamezai RN. Pyruvate kinase M2 and cancer: An updated assessment. FEBS Lett 2014;588:2685-92.  Back to cited text no. 6
Li R, Liu J, Xue H, Huang G. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: A systematic review and meta-analysis. Int J Cancer 2012;131:1837-45.  Back to cited text no. 7
Sithambaram S, Hilmi I, Goh KL. The diagnostic accuracy of the M2 pyruvate kinase quick stool test-A rapid office based assay test for the detection of colorectal cancer. PLoS One 2015;10:e0131616.  Back to cited text no. 8
Cui R, Shi XY. Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value. Int J Clin Exp Pathol 2015;8:11393-9.  Back to cited text no. 9
Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs. colorectal cancer patients. Br J Cancer 2007;96:1329-34.  Back to cited text no. 10
Hardt PD, Ewald N. Tumor M2 pyruvate kinase: A tumor marker and its clinical application in gastrointestinal malignancy. Expert Rev Mol Diagn 2008;8:579-85.  Back to cited text no. 11
Demır AS, Erdenen F, Müderrısoğlu C, Toros AB, Bektaş H, Gelışgen R, et al. Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal cancer. Turk J Gastroenterol 2013;24:36-42.  Back to cited text no. 12